Amphastar Pharmaceuticals (AMPH) EBT (2013 - 2026)

Amphastar Pharmaceuticals' EBT history runs 14 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• On a quarterly basis, EBT fell 67.43% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $102.8 million, a 40.48% decrease from a year earlier, with the FY2025 full-year figure at $123.6 million, down 34.85% from the prior year.
• EBT slipped to $10.1 million in Q1 2026 per AMPH's latest filing, from $31.9 million in the prior quarter.
• Across five years, EBT topped out at $63.6 million in Q3 2023 and bottomed at -$140.6 million in Q4 2023.
• The 5-year median for EBT is $32.8 million (2023), against an average of $25.2 million.
• Across the five-year window, EBT surged 467.72% in 2022 and sank 440.71% in 2023, its largest moves.
• Year by year, EBT stood at $41.3 million in 2022, then sank by 440.71% to -$140.6 million in 2023, then soared by 131.27% to $44.0 million in 2024, then declined by 27.41% to $31.9 million in 2025, then sank by 68.5% to $10.1 million in 2026.
• Per Business Quant, the three latest AMPH EBT figures stand at $10.1 million (Q1 2026), $31.9 million (Q4 2025), and $21.5 million (Q3 2025).